DOCSLIB.ORG

BTS Guideline for Non-CF Bronchiectasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BTS Guideline for Non-CF Bronchiectasis thoraxjnl_65_1S_cover.qxd 6/29/10 3:38 PM Page 1 65 July 2010 Vol 65 Supplement I Vol 65 Supplement I Pages i1–i58 THORAX ThoraxAN INTERNATIONAL JOURNAL OF RESPIRATORY MEDICINE Guideline for non-CF Bronchiectasis British Thoracic Society Bronchiectasis (non-CF) Guideline Group July 2010 thorax.bmj.com Aims and Scope: Thorax enjoys an enviable AN INTERNATIONAL JOURNAL OF RESPIRATORY MEDICINE and longstanding reputation for publishing Journal of the British Thoracic Society clinical and experimental research articles Editor-in-Chief J A Wedzicha (UK) covering many disciplines, including Editor S L Johnston (UK) pathology, immunology and surgery Associate Editors J S Brown (UK) P M A Calverley (UK) International Advisory Board Contact Details M Dusmet (UK) Editorial Office J S Elborn (N Ireland) N Ambrosino (Italy) A Morice (UK) J N Baraniuk (USA) R Panettieri (USA) BMJ Publishing Group Ltd, BMA House, Tavistock A J Fisher (UK) Square London, WC1H 9JR, UK P J Barnes (UK) A Papi (Italy) J M FitzGerald (Canada) T: +44 (0)20 7383 6168 C R W Beasley (New Zealand) N G Papadopoulos (Greece) J A Fleetham (Canada) F: +44 (0)20 7383 6668 J R Britton (UK) M R Partridge (UK) N M Foley (UK) E: [email protected] I Hall (UK) A S Buist (USA) I D Pavord (UK) J R Hurst (UK) E R Chilvers (UK) M G Pearson (UK) R Hubbard (UK) S-H Cho (Korea) T A E Platts Mills (USA) Permissions D A Lomas (UK) S-E Dahlen (Sweden) L Restrick (UK) See http://journals.bmj.com/misc/permissions.dtl D M Mannino (USA) G C Donaldson (UK) D S Robinson (UK) M W Elliott (UK) R M Rudd (UK) F D Martinez (USA) Supplement Enquiries Y Fukuchi (Japan) T A R Seemungal (Trinidad & Tobago) C Robertson (Australia) T: +44 (0)20 7383 6057 B Schonhofer (Germany) D M Geddes (UK) S Sethi (USA) F: +44 (0)20 7554 6795 G A Silvestri (USA) P Goldstraw (UK) T Sethi (UK) E: [email protected] G I Town (New Zealand) R Goldstein (Canada) A K Simonds (UK) M K B Whyte (UK) C Griffiths (UK) P Sliwinski (Poland) J C Hogg (Canada) R A Stockley (UK) For ALL subscription enquiries and orders Statistical Editors S T Holgate (UK) J K Stoller (USA) T: +44 (0)20 7383 6270 J Gibson (UK) P Hopewell (USA) M J Tobin (USA) F: +44 (0)20 7383 6402 L Tata (UK) M Ichinose (Japan) A Torres (Spain) E: [email protected] Images Editors A Kendrick (UK) J Vestbo (Denmark) http://group.bmj.com/group/customerservice/ J M FitzGerald (Canada) T King (USA) E H Walters (Australia) journalhelp/journalhelp J R Mayo (Canada) A J Knox (UK) S T Weiss (USA) J C Hogg (Canada) C K W Lai (China) A Wells (UK) Advertising Letters Editor G J Laurent (UK) JW Wilson (Australia) T: +44 (0)20 7383 6386 J R Hurst (UK) P LeSouef (Australia) A A Woodcock (UK) F: +44 (0)20 7383 6556 Lung Alert Editors W MacNee (UK) M Woodhead (UK) E: [email protected] http://group.bmj.com/group/advertising A Bhowmik (UK) C Mayaud (France) R Zuwallack (USA) J Quint (UK) J Moore-Gillon (UK) Editor, BMJ President, British Thoracic Author Reprints Society Reprints Administrator P Corris T: +44 (0)20 7383 6305 Subscription Information F: +44 (0)207 554 6185 Production Editor E: [email protected] Julia Dimitriou Thorax is published monthly (subscribers receive all supplements) Journal Manager Commercial Reprints (except USA & Canada) Claire Folkes Institutional Rates Personal Rates Nadia Gurney-Randall Publisher 2010 2010 T: +44 (0)20 8445 5825 Julie Solomon M: +44 (0)7866 262344 Print (includes online access at Guidelines for Authors and Print F: +44 (0)20 8445 5870 £491; US$957; 663 no additional cost) E: [email protected] Reviewers £209; US$408; 282 Full instructions are available online Online at http://thorax.bmj.com/ifora. Site licences are priced on FTE Online only Commercial Reprints (USA & Canada) Articles must be submitted basis and allow access by the £115; US$224; 155 Marsha Fogler electronically http://submit-thorax. whole institution. Print is T: +1 800 482 1450 (toll free in the USA) available at deeply discounted ISSN 0040-6376 (print) bmj.com. Authors retain copyright T: +1 856 489 4446 (outside the USA) rates for online subscribers; ISSN 1468-3296 (online) but are required to grant Thorax an F: +1 856 489 4449 details available online at http:// exclusive licence to publish http:// group.bmj.com/group/subs- E: [email protected] thorax.bmj.com/ifora/licence.dtl sales/subscriptions or contact Impact Factor: 7.04 the Subscription Manager in the British Thoracic Society UK (see above right). 17 Doughty Street Personal print or online only and institutional print subscriptions may be London WC1N 2PL, UK purchased online at http://group.bmj.com/group/subs-sales/subscriptions T: +44 (0)20 7831 8778 (payment by (MasterCard/Visa only). F: +44 (0)20 7831 8766 Residents of some EC countries must pay VAT; for details call us or visit E: [email protected] http://group.bmj.com/group/subs-sales/subscriptions/subs-vat http://www.brit-thoracic.org.uk/index.html thoraxjnl_65_1S_titlepage.qxd 6/21/10 6:58 PM Page 1 M C Pasteur, D Bilton, A T Hill On behalf of the British Thoracic Society Bronchiectasis (non-CF) Guideline Group: a sub-group of the British Thoracic Society Standards of Care Committee Contents Volume 65 Issue Suppl I | THORAX July 2010 British Thoracic Society guideline for non-CF bronchiectasis i1 Summary of recommendations Clinical presentation of bronchiectasis Journal of the British Thoracic Society What are the symptoms and signs of Impact Factor: 7.04 Editor-in-Chief i6 Section 1: Introduction bronchiectasis in children? J A Wedzicha (UK) Reason for BTS Bronchiectasis Guideline What symptoms and signs should be assessed Editor in an adult with bronchiectasis? S L Johnston (UK) Guideline Group members Associate Editors How has the Guideline been designed? Investigations directed at underlying J S Brown (UK) J R Hurst (UK) P M A Calverley (UK) D A Lomas (UK) Definition cause M Dusmet (UK) D M Mannino (USA) Why should the underlying cause of J S Elborn (N Ireland) F D Martinez (USA) Methods A J Fisher (UK) C Robertson (Australia) bronchiectasis be established? J M FitzGerald (Canada) B Schonhofer (Germany) J A Fleetham (Canada) G A Silvestri (USA) How common is bronchiectasis in adults and What blood tests should be performed? N M Foley (UK) G I Town (New Zealand) children in the 21st century? I Hall (UK) M K B Whyte (UK) What immunological tests should be done on R Hubbard (UK) What are the pathology and underlying causes? Statistical Editors all patients? L Tata (UK) What is the outlook for these patients? What are the second-line immunological J Gibson (UK) investigations and when should they be Images Editors i8 Section 2: Background and causes J M FitzGerald (Canada) performed? J R Mayo (Canada) Causes and associations When should patients have gastrointestinal J C Hogg (Canada) What underlying causes and associations investigations? Letters Editor should be looked for when investigating When should patients have investigations to J R Hurst (UK) a patient with bronchiectasis? Lung Alert Editors exclude CF? A Bhowmik (UK) Congenital defects of large airways When should patients have tests of ciliary J Quint (UK) Foreign bodies and aspiration President, British Thoracic Society function? What are the best tests to identify P Corris What is the current relevance of previous ciliary defects? Editorial Office severe lower respiratory tract infections to What are the indications for bronchoscopy? BMJ Publishing Group Ltd, BMA House, patients with bronchiectasis? Tavistock Square, London WC1H 9JR, UK Radiological investigations T: +44 (0)20 7383 6147 Mycobacterium tuberculosis and opportunist F: +44 (0)20 7383 6668 mycobacteria What are the important modalities for imaging E: [email protected] bronchiectasis? Immune deficiency and bronchiectasis ISSN: 0040-6376 (print) What is the role of chest x-ray ISSN: 1468-3296 (online) What is the relationship of other airway What is the role of HRCT? Disclaimer: Thorax is owned and published by the diseases to bronchiectasis? British Thoracic Society and BMJ Publishing Group What is an optimum HRCT protocol for defining Ltd, a wholly owned subsidiary of the British Medical What is the relationship of bronchiectasis to Association. The owners grant editorial freedom to bronchiectasis? the Editor of Thorax. cystic fibrosis (CF)? Thorax follows guidelines on editorial What are the HRCT features of bronchiectasis? independence produced by the World Association Which connective tissue disorders are of Medical Editors and the code on good associated with bronchiectasis? Can HRCT identify features of specific causes? publication practice of the Committee on Publication Ethics. Inflammatory bowel diseases How are HRCT changes related to lung Thorax is intended for medical professionals and is provided without warranty, express or implied. function? Statements in the Journal are there sponsibility of Disorders of ciliary function their authors and advertisers and not authors’ How often should radiological investigations be institutions, the BMJ Publishing Group Ltd, the Is a1-antitrypsin deficiency a cause of British Thoracic Society or the BMA unless otherwise repeated? specified or determined by law. Acceptance of bronchiectasis? advertising does not imply endorsement. Radiology in children To the fullest extent permitted by law, the BMJ Yellow nail syndrome Publishing Group Ltd shall not be liable for any loss, What scoring systems should be used for injury or damage resulting from the use of Thorax The upper respiratory tract in bronchiectasis or any information in it whether based on contract, research? tort or otherwise.
Load more

Recommended publications
  • Current Management and Outcome of Tracheobronchial Malacia and Stenosis Presenting to the Paediatric Intensive Care Unit
    Intensive Care Med 52001) 27: 722±729 DOI 10.1007/s001340000822 NEONATAL AND PEDIATRIC INTENSIVE CARE David P.Inwald Current management and outcome Derek Roebuck Martin J.Elliott of tracheobronchial malacia and stenosis Quen Mok presenting to the paediatric intensive care unit Abstract Objective: To identify fac- but was not related to any other fac- Received: 10 July 2000 Final Revision received: 14 Oktober 2000 tors associated with mortality and tor. Patients with stenosis required a Accepted: 24 October 2000 prolonged ventilatory requirements significantly longer period of venti- Published online: 16 February 2001 in patients admitted to our paediat- latory support 5median length of Springer-Verlag 2001 ric intensive care unit 5PICU) with ventilation 59 days) than patients tracheobronchial malacia and with malacia 539 days). stenosis diagnosed by dynamic con- Conclusions: Length of ventilation Dr Inwald was supported by the Medical Research Council. This work was jointly trast bronchograms. and bronchographic diagnosis did undertaken in Great Ormond Street Hos- Design: Retrospective review. not predict survival. The only factor pital for Children NHSTrust, which re- Setting: Tertiary paediatric intensive found to contribute significantly to ceived a proportion of its funding from the care unit. mortality was the presence of com- NHSExecutive; the views expressed in this Patients: Forty-eight cases admitted plex cardiac and/or syndromic pa- publication are those of the authors and not to our PICU over a 5-year period in thology. However, patients with necessarily those of the NHSexecutive. whom a diagnosis of tracheobron- stenosis required longer ventilatory chial malacia or stenosis was made support than patients with malacia.
    [Show full text]
  • Bronchiolitis Obliterans After Severe Adenovirus Pneumonia:A Review of 46 Cases
    Bronchiolitis obliterans after severe adenovirus pneumonia:a review of 46 cases Yuan-Mei Lan medical college of XiaMen University Yun-Gang Yang ( [email protected] ) Xiamen University and Fujian Medical University Aliated First Hospital Xiao-Liang Lin Xiamen University and Fujian Medical University Aliated First Hospital Qi-Hong Chen Fujian Medical University Research article Keywords: Bronchiolitis obliterans, Adenovirus, Pneumonia, Children Posted Date: October 26th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-93838/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/13 Abstract Background:This study aimed to investigate the risk factors of bronchiolitis obliterans caused by severe adenovirus pneumonia. Methods: The First Aliated Hospital of Xiamen University in January, 2019 was collected The clinical data of 229 children with severe adenovirus pneumonia from January to January 2020 were divided into obliterative bronchiolitis group (BO group) and non obstructive bronchiolitis group (non BO group) according to the follow-up clinical manifestations and imaging data. The clinical data, laboratory examination and imaging data of the children were retrospectively analyzed. Results: Among 229 children with severe adenovirus pneumonia, 46 cases were in BO group. The number of days of hospitalization, oxygen consumption time, LDH, IL-6, AST, D-dimer and hypoxemia in BO group were signicantly higher than those in non BO group; The difference was statistically signicant (P < 0.05). Univariate logistic regression analysis showed that there were signicant differences in the blood routine neutrophil ratio, platelet level, Oxygen supply time, hospitalization days, AST level, whether there was hypoxemia, timing of using hormone, more than two bacterial feelings were found in the two groups, levels of LDH, albumin and Scope of lung imaging (P < 0.05).
    [Show full text]
  • SIGN158 British Guideline on the Management of Asthma
    SIGN158 British guideline on the management of asthma A national clinical guideline First published 2003 Revised edition published July 2019 Key to evidence statements and recommendations Levels of evidence 1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1– Meta-analyses, systematic reviews, or RCTs with a high risk of bias 2++ High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal 2+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal 2– Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3 Non-analytic studies, eg case reports, case series 4 Expert opinion Grades of recommendation Note: The grade of recommendation relates to the strength of the supporting evidence on which the evidence is based. It does not reflect the clinical importance of the recommendation. A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results B A body of evidence including studies rated
    [Show full text]
  • The Role of Larygotracheal Reconstruction in the Management of Recurrent Croup in Patients with Subglottic Stenosis
    International Journal of Pediatric Otorhinolaryngology 82 (2016) 78–80 Contents lists available at ScienceDirect International Journal of Pediatric Otorhinolaryngology jo urnal homepage: www.elsevier.com/locate/ijporl The role of larygotracheal reconstruction in the management of recurrent croup in patients with subglottic stenosis a,b,c, a,b a,d,e Bianca Siegel *, Prasad Thottam , Deepak Mehta a Department of Pediatric Otolaryngology, Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA b Children’s Hospital of Michigan, Detroit, MI, USA c Wayne State University School of Medicine Department of Otolaryngology, Detroit, MI, USA d Texas Children’s Hospital, Houston, TX, USA e Baylor University School of Medicine Department of Otolaryngology, Houston, TX, USA A R T I C L E I N F O A B S T R A C T Article history: Objectives: To determine the role of laryngotracheal reconstruction for recurrent croup and evaluate Received 16 October 2015 surgical outcomes in this cohort of patients. Received in revised form 4 January 2016 Methods: Retrospective chart review at a tertiary care pediatric hospital. Accepted 6 January 2016 Results: Six patients who underwent laryngotracheal reconstruction (LTR) for recurrent croup with Available online 13 January 2016 underlying subglottic stenosis were identified through a search of our IRB-approved airway database. At the time of diagnostic bronchoscopy, all 6 patients had grade 2 subglottic stenosis. All patients were Keywords: treated for reflux and underwent esophageal biopsies at the time of diagnostic bronchoscopy; 1 patient Laryngotracheal reconstruction had eosinophilic esophagitis which was treated. All patients had a history of at least 3 episodes of croup Recurrent croup in a 1 year period requiring multiple hospital admissions.
    [Show full text]
  • Diagnostic Issues in Systemic Lupus Erythematosis
    266 Postgrad Med J 2001;77:266–285 Postgrad Med J: first published as 10.1136/pmj.77.906.268 on 1 April 2001. Downloaded from SELF ASSESSMENT QUESTIONS Diagnostic issues in systemic lupus erythematosis N Sofat, C Higgens Answers on p 274. A 24 year old woman was diagnosed with sys- (4) What other tests (apart from 24 hour urine temic lupus erythematosis (SLE) based on a creatinine clearance) are available to measure few months’ history of a photosensitive skin the glomerular filtration rate? rash, predominantly on her face, arthralgia The patient had a 24 hour urinary protein col- involving both hands and wrists, a positive lection, which showed a 24 hour protein measure- antinuclear antibody (ANA) test and a raised ment of 1.8 g. There was no evidence of cellular antinative double stranded DNA antibody casts on urine microscopy. Her blood results were binding level. She was treated with oral as below (normal values are in parentheses): hydroxychloroquine 400 mg daily and short x Sodium 134 mmol/l (135–145) courses of prednisolone during flare-ups. x Potassium 4.5 mmol/l (3.5–5.0) She was reviewed in clinic for her regular x Urea 7.0 mmol/l (2.5–6.7) follow up appointment when she was found to x Creatinine 173 µmol/l (70–115) be hypertensive on repeated measurements of x Haemoglobin 108 g/l (115–160) her blood pressure, an average value being x White cell count 4.5 × 109/l (4.0–11.0) 150/90 mm Hg. She was also urine dipstick x Platelets 130 × 109/l (150–400) positive for blood and protein.
    [Show full text]
  • Left Bronchial with Bronchomalacia, Intractable Wheeze
    Thorax 1991;46:459-461 459 heart disease.7 This report describes a boy Left bronchial who had had intractable wheezing from infancy as a result of widespread discrete areas isomerism associated of bronchomalacia without bronchiectasis, Thorax: first published as 10.1136/thx.46.6.459 on 1 June 1991. Downloaded from and who also had some minor congenital with bronchomalacia, malformations and a rare combination of bronchial, atrial, and abdominal anatomical presenting with arrangements. We report this case because of the unusual anatomy and other congenital intractable wheeze malformations, and to emphasise the care needed in assessing wheezy children. Philip Lee, Andrew Bush, John 0 Warner Case report This 12 year old boy was referred as a case of steroid resistant asthma. He had had recurrent episodes of coughing and noisy breathing from the age of 5 months, usually precipitated by an upper respiratory infection. At 22 months a Abstract murmur was noted during an episode of right The cause of the Williams Campbell syn- lower lobe pneumonia, and he subsequently drome (bronchomalacia with bronchi- underwent ligation ofa patent arterial duct. He ectasis) is controversial. A boy with subsequently developed wheezing in the early bronchomalacia, bifid ribs, and left bron- morning, a chronic cough, and breathlessness chial isomerism presented with intract- on minimal exertion, despite inhaling sal- able wheeze mimicking asthma. The butamol and beclomethasone. A trial of oral combination of the abdominal, bron- prednisolone, 30 mg daily for one week, failed chial, and atrial anatomy seen in this to improve his symptoms. The only physical child has been described only once finding of note was widespread inspiratory and previously.
    [Show full text]
  • A Professional Development Framework for Paediatric Respiratory Nursing
    A professional development framework for paediatric respiratory nursing ISSN 2040-2023: British Thoracic Society Reports Vol 12, Issue 2, May 2021 1 ACKNOWLEDGEMENTS: We are grateful to colleagues at the National Paediatric Respiratory and Allergy Nurses Group (NPRANG) for their support with the development of this document. In particular: Ann McMurray Asthma Nurse Specialist, Royal Hospital for Children and Young People, Edinburgh. NPRANG Chair Bethan Almeida Clinical Nurse Specialist for Paediatric Asthma and Allergy, Imperial College Healthcare NHS Trust Tricia McGinnity Paediatric Cystic Fibrosis Nurse Specialist, Southampton Children's Hospital Emma Bushell Paediatric Respiratory Nurse Specialist – Asthma, Frimley Health NHS Foundation Trust This document has been adapted from the following publication: British Thoracic Society, A professional development framework for respiratory nursing (1). The authors of this original document are: Samantha Prigmore, Co-chair Consultant respiratory nurse, St Georges University Hospitals NHS Foundation Trust Helen Morris, Co-chair ILD nurse specialist, Wythenshawe Hospital Alison Armstrong Nurse consultant (assisted ventilation), Royal Victoria Infirmary Susan Hope Respiratory nurse specialist, Royal Stoke University Hospital Karen Heslop-Marshall Nurse consultant, Royal Victoria Infirmary Jacqui Pollington Respiratory nurse consultant, Rotherham NHS Foundation Trust CONTENTS: Introduction Method of production How to use this document Competency table (Band 5, 6, 7 and 8) Supporting evidence Acknowledgements Declarations of Interest References Content from this document may be reproduced with permission from BTS as long as you conform to the following conditions: • The text must not be altered in any way. • The correct acknowledgement must be included. 2 Introduction Paediatric respiratory nurses are an important component of the multi-professional team for a wide variety of respiratory conditions, providing holistic care for patients in a variety of settings.
    [Show full text]
  • New Jersey Chapter American College of Physicians
    NEW JERSEY CHAPTER AMERICAN COLLEGE OF PHYSICIANS ASSOCIATES ABSTRACT COMPETITION 2015 SUBMISSIONS 2015 Resident/Fellow Abstracts 1 1. ID CATEGORY NAME ADDITIONAL PROGRAM ABSTRACT AUTHORS 2. 295 Clinical Abed, Kareem Viren Vankawala MD Atlanticare Intrapulmonary Arteriovenous Malformation causing Recurrent Cerebral Emboli Vignette FACC; Qi Sun MD Regional Medical Ischemic strokes are mainly due to cardioembolic occlusion of small vessels, as well as large vessel thromboemboli. We describe a Center case of intrapulmonary A-V shunt as the etiology of an acute ischemic event. A 63 year old male with a past history of (Dominik supraventricular tachycardia and recurrent deep vein thrombosis; who has been non-compliant on Rivaroxaban, presents with Zampino) pleuritic chest pain and was found to have a right lower lobe pulmonary embolus. The deep vein thrombosis and pulmonary embolus were not significant enough to warrant ultrasound-enhanced thrombolysis by Ekosonic EndoWave Infusion Catheter System, and the patient was subsequently restarted on Rivaroxaban and discharged. The patient presented five days later with left arm tightness and was found to have multiple areas of punctuate infarction of both cerebellar hemispheres, more confluent within the right frontal lobe. Of note he was compliant at this time with Rivaroxaban. The patient was started on unfractionated heparin drip and subsequently admitted. On admission, his vital signs showed a blood pressure of 138/93, heart rate 65 bpm, and respiratory rate 16. Cardiopulmonary examination revealed regular rate and rhythm, without murmurs, rubs or gallops and his lungs were clear to auscultation. Neurologic examination revealed intact cranial nerves, preserved strength in all extremities, mild dysmetria in the left upper extremity and an NIH score of 1.
    [Show full text]
  • 17Th & 18Th June 2021 Speakers' Details and Presentation Summaries
    th th SUMMER MEETING ONLINE – 17 & 18 June 2021 Speakers’ Details and Presentation Summaries The following details are in programme order. Use the PDF search button to quickly find a session or speaker. OPEN SESSION – NATIONAL ASTHMA AND COPD AUDIT PROGRAMME Thursday 17th June: 08:00-09:00 Dr James Calvert qualified in Medicine from Oxford Session aims and overview University in 1992. He studied Public Health as a 1) To summarise the main findings of the 2020/21 Fulbright Scholar at Harvard University before NACAP reports. completing his PhD in Asthma Epidemiology in South 2) To outline the QI support opportunities offered by Africa and London. NACAP to clinical and audit teams. He was a Consultant Respiratory Specialist in Bristol from 2006-2021. He is now a Respiratory Consultant Professor Roberts will present a summary of key and Medical Director of Aneurin Bevan University reported findings from across the audits from the last Health Board in Wales. 12 months, highlighting areas for further James has worked with colleagues in the South West improvement. He will speak about the impact of and at NHS England to improve access to integrated COVID-19 on standards of care and on audit services for respiratory patients. He has Chaired the participation, along with plans to improve automated British Thoracic Society (BTS) Professional and extraction of NACAP data. Organisational Standards Committee and has been Dr Calvert will talk about the QI programme to be the BTS National Audit Lead. He has a longstanding launched this year. interest in quality improvement in health care and has A discussion will follow around ideas for improving worked with the BTS, NHS Improving Value, the Royal NACAP support to clinical and audit teams.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation
    Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation Dr Rohit Bazaz National Aspergillosis Centre, UK Manchester University NHS Foundation Trust/University of Manchester ~ ABPA -a41'1 Severe asthma wl'th funga I Siens itisat i on Subacute IA Chronic pulmonary aspergillosjs Simp 1Ie a:spe rgmoma As r§i · bronchitis I ram une dysfu net Ion Lun· damage Immu11e hypce ractivitv Figure 1 In t@rarctfo n of Aspergillus Vliith host. ABP A, aHerg tc broncho pu~ mo na my as µe rgi ~fos lis; IA, i nvas we as ?@rgiH os 5. MANCHl·.'>I ER J:-\2 I Kosmidis, Denning . Thorax 2015;70:270–277. doi:10.1136/thoraxjnl-2014-206291 Allergic Fungal Airway Disease Phenotypes I[ Asthma AAFS SAFS ABPA-S AAFS-asthma associated with fu ngaIsensitization SAFS-severe asthma with funga l sensitization ABPA-S-seropositive a llergic bronchopulmonary aspergi ll osis AB PA-CB-all ergic bronchopulmonary aspergi ll osis with central bronchiectasis Agarwal R, CurrAlfergy Asthma Rep 2011;11:403 Woolnough K et a l, Curr Opin Pulm Med 2015;21:39 9 Stanford Lucile Packard ~ Children's. Health Children's. Hospital CJ Scanford l MEDICINE Stanford MANCHl·.'>I ER J:-\2 I Aspergi 11 us Sensitisation • Skin testing/specific lgE • Surface hydroph,obins - RodA • 30% of patients with asthma • 13% p.atients with COPD • 65% patients with CF MANCHl·.'>I ER J:-\2 I Alternar1a• ABPA •· .ABPA is an exagg·erated response ofthe imm1une system1 to AspergUlus • Com1pUcatio n of asthm1a and cystic f ibrosis (rarell·y TH2 driven COPD o r no identif ied p1 rior resp1 iratory d isease) • ABPA as a comp1 Ucation of asth ma affects around 2.5% of adullts.
    [Show full text]
  • Disparities in Respiratory Health
    American Thoracic Society Documents An Official American Thoracic Society/European Respiratory Society Policy Statement: Disparities in Respiratory Health 6 Dean E. Schraufnagel, Francesco Blasi, Monica Kraft, Mina Gaga, Patricia Finn, Klaus Rabe This official statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was approved by the ATS Board of Directors, XXXXXXXXX, and by the ERS XXXXXXXX, XXXXXXXXXX [[COMP: Insert internal ToC]] 1 Abstract Background: Health disparities, defined as a significant difference in health between populations, are more common for diseases of the respiratory system than for those of other organ systems because of the environmental influence on breathing and the variation of the environment among different segments of the population. The lowest social groups are up to 14 times more likely to have respiratory diseases than are the highest. Tobacco smoke, air pollution, environmental exposures, and occupational hazards affect the lungs more than other organs and occur disproportionately in ethnic minorities and those with lower socioeconomic status. Lack of access to quality health care contributes to disparities. Methods: The executive committees of the American Thoracic Society (ATS) and European Respiratory Society (ERS) established a writing committee to develop a policy on health disparities. The document was reviewed, edited, and approved by their full executive committees and boards of directors of the societies. Results: This document expresses a policy to address health disparities by promoting scientific inquiry and training, disseminating medical information and best practices, and monitoring and advocating for public respiratory health. ERS and ATS have strong international commitments and work with leaders from governments, academia, and other organizations to address and reduce avoidable health inequalities.
    [Show full text]
  • Problem Based Review: Pleuritic Chest Pain
    172 Acute Medicine 2012; 11(3): 172-182 Trainee Section 172 Problem based review: Pleuritic Chest Pain RW Lee, LE Hodgson, MB Jackson & N Adams Abstract Pleuritic pain, a sharp discomfort near the chest wall exacerbated by inspiration is associated with a number of pathologies. Pulmonary embolus and infection are two common causes but diagnosis can often be challenging, both for experienced physicians and trainees. The underlying anatomy and pathophysiology of such pain and the most common aetiologies are presented. Clinical symptoms and signs that may arise alongside pleuritic pain are then discussed, followed by an introduction to the diagnostic tools such as the Wells’ score and current guidelines that can help to select the most appropriate investigation(s). Management of pulmonary embolism and other common causes of pleuritic pain are also discussed and highlighted by a clinical vignette. Keywords Pleuritic pain, pulmonary embolus, pleurisy, chest pain Key Points 1. Pleuritic chest pain is a common reason for presentation to hospital. 2. Pulmonary embolism is a common, potentially life-threatening cause but can be difficult to diagnose, with clear overlap Richard William Lee between typical presentations. MBBS, MRCP, MA 3. Excluding other differential diagnoses can be difficult without definitive investigation e.g. CT Pulmonary Angiography (Cantab.) (CTPA). Respiratory Registrar, 4. Clinical probability and scoring systems (e.g. Wells’ score) can assist the physician in further management. Darent Valley Hospital 5. Several key guidelines from the thoracic and cardiological societies provide useful algorithms for investigation and further reading. Luke Eliot Hodgson MBBS, MRCP, MSc Respiratory Registrar, Introduction Brighton & Sussex Case History University Hospitals NHS Pleuritic pain is a sharp, ‘catching’ pain perceived A 37 year-old male smoker, with no previous medical Trust.
    [Show full text]